---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-061958"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:51:08.674925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Q1 net loss narrows to $17.7M; FDA accepts DFD-29 NDA for rosacea

## Summary
- Consolidated net revenue $13.0M, all from dermatology products, up 7% YoY driven by Qbrexza and Accutane.
- Net loss attributable to common stockholders $(17.7)M ($1.03/share) vs $(23.5)M ($3.47/share) in Q1 2023.
- Cash and equivalents $85.8M as of March 31, up from $83.4M; includes $11M January direct offering.
- FDA accepted DFD-29 NDA with PDUFA date Nov 4, 2024; potential only oral therapy for rosacea lesions and erythema.
- Triplex CMV vaccine Phase 2 for HIV/CMV fully enrolled; topline data Q4 2024; liver transplant trial dosed first patient.

## SEC filing metadata
- accession: 0001104659-24-061958
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465924061958/0001104659-24-061958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465924061958/tm2414584d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-061958
- JSON: https://secwatch.observer/filing/0001104659-24-061958.json
- Plain text: https://secwatch.observer/filing/0001104659-24-061958.txt

## Key facts
- Earnings Releases
  Fortress Biotech, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465924061958/0001104659-24-061958-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.